Aclaris Therapeutics Says Phase 1 Trial of Dermatitis Therapy Candidate ATI-052 Shows 'Strong Safety' Profile

MT Newswires Live01-06 21:02

Aclaris Therapeutics (ACRS) said Tuesday its atopic dermatitis and asthma therapy candidate ATI-052 showed a 'strong safety and tolerability profile' in interim phase 1 trial results.

The interim data also showed the candidate had a 'dose proportional pharmokinetic profile, and concentration-dependent pharmacodynamics even at the lowest dose.'

Aclaris plans to initiate phase 1b trials for atopic dermatitis 'imminently' and asthma therapy in Q1, with top line data from both trials to be released in H2.

The company is also planning a phase 2b trial of ATI-052 in atopic dermatitis to begin in H2.

Shares of the company were up 3.4% in recent Tuesday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601937897?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601937897","market":"sg","top_or_hot":-1,"title":"Aclaris Therapeutics Says Phase 1 Trial of Dermatitis Therapy Candidate ATI-052 Shows 'Strong Safety' Profile","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ACRS\">Aclaris Therapeutics</a> (ACRS) said Tuesday its atopic dermatitis and asthma therapy candidate ATI-052 showed a 'strong safety and tolerability profile' in interim phase 1 trial results.</p><p>The interim data also showed the candidate had a 'dose proportional pharmokinetic profile, and concentration-dependent pharmacodynamics even at the lowest dose.'</p><p>Aclaris plans to initiate phase 1b trials for atopic dermatitis 'imminently' and asthma therapy in Q1, with top line data from both trials to be released in H2.</p><p>The company is also planning a phase 2b trial of ATI-052 in atopic dermatitis to begin in H2.</p><p>Shares of the company were up 3.4% in recent Tuesday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aclaris Therapeutics Says Phase 1 Trial of Dermatitis Therapy Candidate ATI-052 Shows 'Strong Safety' Profile</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAclaris Therapeutics Says Phase 1 Trial of Dermatitis Therapy Candidate ATI-052 Shows 'Strong Safety' Profile\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-06 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ACRS\">Aclaris Therapeutics</a> (ACRS) said Tuesday its atopic dermatitis and asthma therapy candidate ATI-052 showed a 'strong safety and tolerability profile' in interim phase 1 trial results.</p><p>The interim data also showed the candidate had a 'dose proportional pharmokinetic profile, and concentration-dependent pharmacodynamics even at the lowest dose.'</p><p>Aclaris plans to initiate phase 1b trials for atopic dermatitis 'imminently' and asthma therapy in Q1, with top line data from both trials to be released in H2.</p><p>The company is also planning a phase 2b trial of ATI-052 in atopic dermatitis to begin in H2.</p><p>Shares of the company were up 3.4% in recent Tuesday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATI","symbol_name":"阿利根尼","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2601937897","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601937897","pubTimestamp":1767704534,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Aclaris Therapeutics  said Tuesday its atopic dermatitis and asthma therapy candidate ATI-052 showed a 'strong safety and tolerability profile' in interim phase 1 trial results.The interim data also showed the candidate had a 'dose proportional pharmokinetic profile, and concentration-dependent pharmacodynamics even at the lowest dose.'Aclaris plans to initiate phase 1b trials for atopic dermatitis 'imminently' and asthma therapy in Q1, with top line data from both trials to be released in H2.The company is also planning a phase 2b trial of ATI-052 in atopic dermatitis to begin in H2.Shares of the company were up 3.4% in recent Tuesday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATI":"阿利根尼","BK4006":"钢铁","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","ACRS":"Aclaris Therapeutics","BK4187":"航天航空与国防","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","BK4007":"制药"},"translate_title":"Aclaris Therapeutics表示皮炎候选疗法ATI-052的1期试验显示出“强大的安全性”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATI":1.5,"ACRS":1.5},"content_text":"Aclaris Therapeutics (ACRS) said Tuesday its atopic dermatitis and asthma therapy candidate ATI-052 showed a 'strong safety and tolerability profile' in interim phase 1 trial results.The interim data also showed the candidate had a 'dose proportional pharmokinetic profile, and concentration-dependent pharmacodynamics even at the lowest dose.'Aclaris plans to initiate phase 1b trials for atopic dermatitis 'imminently' and asthma therapy in Q1, with top line data from both trials to be released in H2.The company is also planning a phase 2b trial of ATI-052 in atopic dermatitis to begin in H2.Shares of the company were up 3.4% in recent Tuesday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601937897","isCrawlerRequest":true}